Welcome to our dedicated page for Horizon Space Acquisition II SEC filings (Ticker: HSPT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Horizon Space Acquisition II's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Horizon Space Acquisition II's regulatory disclosures and financial reporting.
SL Science Holding Limited has filed a Form F-4 to register ordinary shares to be issued in a two-step business combination among itself, Horizon Space Acquisition II Corp. (HSPT) and SL BIO Ltd. After closing, HSPT and SL Bio will become subsidiaries of SL Science Holding, whose ordinary shares are expected to trade on the Nasdaq Global Market under the symbol “SLBT.”
The exchange ratio for SL Bio shareholders is based on a valuation reference of $5.568 billion at $10.00 per PubCo share, while each HSPT ordinary share will convert into one PubCo ordinary share after unit separation and right conversion. The deal targets at least $5,000,000 of third‑party equity “Transaction Financing,” and HSPT public shareholders may redeem their shares for cash from the trust account subject to a 15% cap for any group. Post‑merger, CEO William Wang is expected to hold about 58% of PubCo’s voting power, making it a “controlled company” and a Cayman‑incorporated foreign private issuer with lighter U.S. governance and reporting requirements; the board obtained a fairness opinion from King Kee Appraisal and Advisory Limited in supporting the transaction.
Horizon Space Acquisition II Corp. entered into a new unsecured promissory note for
Horizon Space Acquisition II Corp. (HSPT) filed its quarterly report for the period ended September 30, 2025. The SPAC remains pre‑revenue, with activity centered on its IPO proceeds and proposed merger plans. Net income was $615,026 for the quarter, driven by $739,550 of interest and dividend income from the Trust Account, offset by $124,524 of formation and operating costs. For the nine months, net income totaled $1,308,900.
The Trust Account balance was $71,540,599, while cash outside the trust was $66,627. Ordinary shares subject to possible redemption were 6,900,000 at redemption value; non‑redeemable ordinary shares outstanding were 2,180,000. The company reported a working capital deficit of $436,294 and recorded accretion to redemption value of $739,550 in the quarter.
Management disclosed substantial doubt about the company’s ability to continue as a going concern. The combination deadline is November 18, 2025 (extendable to May 18, 2026 with sponsor deposits of $690,000 per three‑month extension, up to $1,380,000). On May 9, 2025, HSPT entered a business combination agreement with SL Science Holding Limited and SL Bio Ltd. The sponsor provided a $300,000 non‑interest bearing working capital note on July 5, 2025.
Horizon Space Acquisition II Corp. is a Cayman Islands blank‑check company formed to complete a business combination. The company completed an IPO and related private placements that produced gross proceeds of $69,000,000 and, as of June 30, 2025, held $70,801,049 in a Trust Account that will fund an initial business combination. Cash outside the Trust was $26,030 and the company reported a working capital deficit of $311,770.
The company reported net income of $221,282 for Q2 2025 and $693,874 for the six months ended June 30, 2025, primarily from interest and dividend income on the Trust Account of $730,448 (Q2) and $1,456,519 (six months). On May 9, 2025, the company entered into a business combination agreement with SL Bio (through PubCo), and on July 5, 2025 the sponsor provided a $300,000 unsecured promissory note for working capital. Management disclosed that conditions raise substantial doubt about the company’s ability to continue as a going concern and plans to address this through working capital loans.
Mizuho Financial Group reports beneficial ownership of 629,000 common shares of Horizon Space Acquisition II Corp., representing 6.9% of the class. The filing states Mizuho has sole voting and sole dispositive power over these shares, which are directly held by Mizuho Securities USA LLC and may be indirectly owned by related Mizuho entities.
The statement classifies Mizuho as a parent holding company and affirms the securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.
W. R. Berkley Corporation and Berkley Insurance Company reported beneficial ownership of 674,346 ordinary shares of Horizon Space Acquisition II Corp., representing 7.4% of the class based on the issuer's publicly reported 9,080,000 ordinary shares outstanding. The reported position shows 0 sole voting or dispositive power and 674,346 in shared voting and dispositive power.
The filing states the securities were acquired and are held in the ordinary course of business and were not acquired to change or influence control of the issuer. Reporting persons are organized in Delaware and list a principal address in Greenwich, Connecticut.
FAQ
What is the current stock price of Horizon Space Acquisition II (HSPT)?
What is the market cap of Horizon Space Acquisition II (HSPT)?
